Literature up to march 2017 was reviewed, and recommendations and supplemental information were updated. This current document focuses on dpyd and is intended to provide guidance to clinical laboratories and assay manufacturers who develop, validate, and/or offer clinical dpyd pharmacogenomic testing. Genetic testing for common pathogenic dpyd variants has been proposed as a means of identifying individuals at risk of severe fluoropyrimidine toxicity The clinical pharmogenetics implementation consortium (cpic) created guidelines on dpyd genotype guided fluoropyrimidine dosing. Cpic guideline for fluoropyrimidines based on dpyd genotype Dpyd allele definition, allele functionality, and frequency tables) see guideline pages or pharmgkb.
Nearly 4 decades later, the national comprehensive cancer network (nccn) has issued updated clinical guidelines that embrace dpyd genotyping as a tool for tailoring fluoropyrimidine chemotherapy. Clinical pharmacogenetics implementation consortium (cpic) guideline for diphydropyrimidine dehydrogenase genotype and fluropyrimidine dosing This page contains reference files created by clinpgx/cpic The files support cpic guidelines, but are also general resources for dpyd See all genes with information tables. Cpic guidelines are designed to help clinicians understand how available genetic test results should be used to optimize drug therapy, rather than whether tests should be ordered.
OPEN
